聚焦超声治疗宫颈持续高危型HPV感染

 研究了聚焦超声用于治疗宫颈持续高危型HPV感染的有效性和安全性。通过入组跟踪研究方式，将宫颈高危性HPV感染患者90例随机分为3组（每组30例），分别采用聚焦超声、干扰素治疗及假辐照，分别于治疗后3个月、6个月检测各组的缓解率、转阴率及无效率。结果显示：治疗后3个月，聚焦超声治疗组转阴率为53.3%，干扰素治疗组转阴率48.3%。假辐照组转阴率为31.0%（P＜0.05）。治疗后6个月，聚焦超声治疗组转阴率为86.2%，干扰素治疗组转阴率79.3%，假辐照组转阴率53.6%。与假辐照组对比，聚焦超声及干扰素均能显著降低宫颈高危型HPV感染患者的HPV滴度（P＜0.05），聚焦超声与干扰素组疗效之间无显著差异（P＞0.05）。由此得出结论：聚焦超声能安全有效地控制宫颈高危型HPV的持续感染。

Clinical Study of Focused Ultrasound to Treat High-risk Cervical HPV Infection

In order to study the therapeutic effect of focused ultrasound on cervical High-Risk HPV (HR-HPV) infection, a total of 90 women with high-risk cervical HPV infection were divided randomly into the ultrasound group (30 cases), the interferon group (30 cases) and the control group with no treatment(30 cases). The remission, ineffective and negative rates were compared in the third and sixth months after treatment. It is shown that in the third month, the negative rate was 53.3% for the ultrasound group, 48.3% for the interferon treatment and 31.0% for the control group. In the sixth month, the negative rate was changed to 86.2% for the ultrasound group, 79.3% for the interferon treatment and 53.6% for the control group. Compared with the control group, both ultrasound and α-2b interferon can reduce the titre of HR-HPV(P<0.05). There is no obvious difference between ultrasound and α-2b interferon groups(P>0.05). The results show that the ultrasound treatment can control the infection of cervical HR-HPV effectively and safely.